Cognitive Dysfunction Clinical Trial
— MINDOfficial title:
Multiple Interventions to Prevent Cognitive Decline
The investigators aim to test the feasibility of a pragmatic non-pharmacological strategy,
that may prevent cognitive decline in patients with mild cognitive impairment. This strategy
is based on five different interventions: cognitive training, physical activity, nutrition
education, adaption to memory loss, diagnosis and correction of hearing impairment.
A quasi-experimental study will be implemented in Porto (Portugal), including patients that
fulfill all of the following criteria: a) age 18-85 years; b) Montreal Cognitive Assessment
(MoCA) score greater than or equal to two standard deviations below the normative reference
value for the corresponding age and education level in the Portuguese population OR diagnosis
of Mild Cognitive Impairment, performed by a Neurologist, during the six previous months,
considering the results of a neuropsychological battery; c) Cardiovascular Risk Factors,
Aging and Dementia (CAIDE) Dementia Risk Score of at least six points. Patients who have any
medical disability that contraindicates physical activity or have a lack of autonomy in daily
activities will be excluded.
The program will be implemented in groups of 10 participants, over a period of 10 consecutive
months.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | December 2020 |
Est. primary completion date | August 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion criteria: a) Age 18-85 years; b1) Montreal Cognitive Assessment score = to two standard deviations below the normative reference value for the corresponding age and education level in the Portuguese population; OR b2) clinical diagnosis of Mild Cognitive Impairment; c) Cardiovascular Risk Factors, Aging and Dementia Dementia Risk Score = six points. Exclusion criteria: 1. medical disability that contraindicates physical activity; 2. lack of autonomy in daily activities. |
Country | Name | City | State |
---|---|---|---|
Portugal | Agrupamento de Centros de Saúde do Porto Ocidental | Porto |
Lead Sponsor | Collaborator |
---|---|
Universidade do Porto |
Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cognitive performance 1 | Variation of participant's cognitive performance assessed using the Montreal Cognitive Assessment, between the baseline assessment and the end of follow-up. This scale varies from 0 (worst cognitive performance) to 30 points (best cognitive performance). | 10 months | |
Primary | Body mass index | Variation of participant's body mass index between the baseline assessment and the end of follow-up. | 10 months | |
Primary | Adherence to the Mediterranean diet | Variation of participant's self-reported adherence to the Mediterranean diet, assessed using the Mediterranean food pattern (PREDIMED) scale, between the baseline assessment and the end of follow-up. This scale varies from 0 (lowest adherence to the Mediterranean diet) to 14 points (highest adherence to the Mediterranean diet). A score over 10 points indicates good adherence to the Mediterranean diet. | 10 months | |
Primary | Number of steps | Variation of participant's number of steps, assessed using a portable accelerometer, between the baseline assessment and the end of follow-up. | 10 months | |
Primary | Adherence to each intervention | Proportion of adherence to each intervention and component of each intervention, calculated as the number of sessions attended/total number of sessions implemented. For remote cognitive training the outcome will be the absolute number of sessions. | 10 months | |
Primary | Dropout | Proportion of participants who dropped out of the study, calculated as the number of participants who dropped out after attending at least one session/total number of participants who attended at least one session. | 10 months | |
Secondary | Cognitive performance 2 | Variation of participant's cognitive performance assessed using a neuropsychological battery, between the baseline assessment and the end of follow-up. This will be reported in the format of a Z-score, assuming positive and negative values. Higher scores indicate better cognitive performance. | 10 months | |
Secondary | Memory complaints | Variation of the self-reported memory complaints, assessed using the self-reported memory complaints scale, between the baseline assessment and the end of follow-up. This scale varies from 0 (best score) to 21 points (worst score). Scores over three points indicate the presence of self-reported memory complaints. | 10 months | |
Secondary | Anxiety and depression | Variation of the anxiety and depression scores, assessed using the Hospital Anxiety and Depression Scale (HADS), between the baseline assessment and the end of follow-up. This scale varies from 0 (best score) to 21 points (worst score). | 10 months | |
Secondary | Reported quality of life: EQ-5D scale | Variation of participant's quality of life, assessed using the EuroQol Group scale - 5 dimensions (EQ-5D) scale, between the baseline assessment and 10 months after the beginning of the intervention. This is assessed using two subscales: a) five multiple choice questions, with five response possibilities, which produce a score that varies from 5 (best score) to 25 points (worst score); b) visual analogic scale, that varies from 0 (worst score) to 100 (best score). | 10 months | |
Secondary | Handgrip strength | Variation of participant's handgrip strength, assessed using a dynamometer, between the baseline assessment and 10 months after the beginning of the intervention. | 10 months | |
Secondary | Agility 1 | Variation of participant's agility and balance, assessed using the Time Up and Go Test scale, between the baseline assessment and 10 months after the beginning of the intervention. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score). | 10 months | |
Secondary | Agility 2 | Variation of participant's agility and balance, assessed using the One Leg Balance Test, between the baseline assessment and 10 months after the beginning of the intervention. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score). | 10 months | |
Secondary | Time of follow-up | Number of days between the first and the last session attended by the participant. | 10 months | |
Secondary | Implemented sessions | Proportion of sessions implemented, calculated as the number of sessions that the research team was able to implement/total number of sessions planned. | 10 months | |
Secondary | Complete assessment of participants | For each study outcome, proportion of participants with complete information, calculated at baseline and different moments of follow-up, as the number of participants with complete information/total number of participants evaluated. | 10 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05273125 -
MOBility Disorders Assessment in Patients With Mild COGnitive Disorders
|
||
Active, not recruiting |
NCT04049695 -
Improving Cognition After Cancer
|
N/A | |
Completed |
NCT05912374 -
Adapting a Behavioral Intervention to Accommodate Cognitive Dysfunction in People Who Inject Drugs
|
N/A | |
Recruiting |
NCT03977350 -
Association Between qEEG Measure and Post-Operative Cognitive Dysfunction (POCD) and Postoperative Delirium (POD)
|
||
Not yet recruiting |
NCT06027632 -
Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer
|
N/A | |
Terminated |
NCT00754052 -
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
|
Phase 3 | |
Terminated |
NCT00754013 -
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
|
Phase 3 | |
Completed |
NCT00719628 -
Depth of Anaesthesia and Cognitive Dysfunction
|
N/A | |
Recruiting |
NCT05014399 -
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
|
||
Completed |
NCT04966455 -
Effect of Raisins on Cognitive Function in Healthy Older Adults
|
Phase 3 | |
Recruiting |
NCT05372159 -
Vanderbilt Memory and Aging Project
|
||
Completed |
NCT03243279 -
BRS and Outcomes in Cardiothoracic Surgery
|
||
Completed |
NCT04093882 -
The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease
|
||
Recruiting |
NCT05732285 -
A Pilot Randomized Controlled Trial: CoINTEGRATE
|
N/A | |
Completed |
NCT06059768 -
Urdu Translation and Psychometric Analysis of Lawton IADLS.
|
||
Completed |
NCT04624529 -
Validity and Reliability of a Self-evaluation Tool for Cognitive Deficits in the Acute Stage After Stroke
|
||
Completed |
NCT04562662 -
Evaluation of mediVR-KAGURA Guided Therapy
|
N/A | |
Active, not recruiting |
NCT04638101 -
Building the Path to Resilience in Preterm Infants: Mindfulness-based Intervention
|
N/A | |
Active, not recruiting |
NCT04556305 -
Lifestyle Physical Activity and Cognitive Training Interventions
|
N/A | |
Completed |
NCT03933475 -
Telerehabilitation for Cognitive Impairment Following Acquired Brain Injury
|
N/A |